OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial

Burosumab, a fully human IgG1 monoclonal antibody to FGF23, is approved in Canada and Brazil to treat XLH in patients ≥1 year of age and in the US to treat XLH in patients ≥6 months of age. Burosumab has also received conditional marketing authorization in Europe to treat XLH with radiographic evide...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Perwad, Farzana, Portale, Anthony A, Carpenter, Thomas O, Briot, Karine, Imel, Erik Allen, Kamenicky, Peter, Weber, Thomas Joseph, Pitukcheewanont, Pisit, Cheong, Hae Il, De Beur, Suzanne Marie Jan, Imanishi, Yasuo, Ito, Nobuaki, Lachmann, Robin, Tanaka, Hiroyuki, Zhang, Lin, Skrinar, Alison, Rees, Linda, Insogna, Karl Leonard
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Bone and Mineral Metabolism
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209551/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.147
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados